Cargando…
Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer
High-dose-rate brachytherapy (HDR-BT) with external beam radiation therapy (EBRT) is a common treatment option for locally advanced prostate cancer (PCa). Seventy-nine male patients (median age 71 years, range 50 to 79) with high-risk PCa underwent HDR-BT following EBRT between December 2009 and Jan...
Autores principales: | Ecke, Thorsten H., Huang-Tiel, Hui-Juan, Golka, Klaus, Selinski, Silvia, Geis, Berit Christine, Koswig, Stephan, Bathe, Katrin, Hallmann, Steffen, Gerullis, Holger |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133879/ https://www.ncbi.nlm.nih.gov/pubmed/27834929 http://dx.doi.org/10.3390/ijms17111879 |
Ejemplares similares
-
Health-related quality of life and rates of toxicity after high-dose-rate brachytherapy in combination with external beam radiation therapy for high-risk prostate cancer
por: Huang-Tiel, Hui-Juan, et al.
Publicado: (2020) -
A case of CRPC with multiple bladder invasions treated with EBRT followed by HDR-BT boost
por: Takagawa, Yoshiaki, et al.
Publicado: (2022) -
Vital role of volume and number of needles in HDR brachytherapy (HDR-BT) of prostate cancer
por: Chicheł, Adam, et al.
Publicado: (2009) -
Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer
por: Burchardt, Wojciech, et al.
Publicado: (2018) -
The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer
por: Yoshioka, Yasuo, et al.
Publicado: (2013)